Alkaptonuria: Current Perspectives
Open Access
- 1 January 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in The Application of Clinical Genetics
- Vol. ume 13, 37-47
- https://doi.org/10.2147/TACG.S186773
Abstract
The last 15 years have been the most fruitful in the history of research on the metabolic disorder alkaptonuria (AKU). AKU is caused by a deficiency of homogentisate dioxygenase (HGD), the enzyme involved in metabolism of tyrosine, and is characterized by the presence of dark ochronotic pigment in the connective tissue that is formed, due to high levels of circulating homogentisic acid. Almost 120 years ago, Sir Archibald Garrod used AKU to illustrate the concept of Mendelian inheritance in man. In January 2019, the phase III clinical study SONIA 2 was completed, which tested the effectiveness and safety of nitisinone in the treatment of AKU. Results were positive, and they will serve as the basis for the application for registration of nitisinone for treatment of AKU at the European Medicines Agency. Therefore, AKU might become a rare disease for which a cure will be found by 2020. We understand the natural history of the disease and the process of ochronosis much more, but at the same time there are still unanswered questions. One of them is the issue of the factors influencing the varying severity of the disease, since our recent genotype–phenotype study did not show that differences in residual homogentisic acid activity caused by the different mutations was responsible. Although nitisinone has proved to arrest the process of ochronosis, it has some unwanted effects and does not cure the disease completely. As such, enzyme replacement or gene therapy might become a new focus of AKU research, for which a novel suitable mouse model of AKU is available already. We believe that the story of AKU is also a story of effective collaboration between scientists and patients that might serve as an example for other rare diseases.Keywords
This publication has 50 references indexed in Scilit:
- Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease—A reviewJournal of Inherited Metabolic Disease, 2019
- Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreMolecular Genetics and Metabolism, 2018
- Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric MicePublished by Springer Science and Business Media LLC ,2015
- Urine homogentisic acid and tyrosine: Simultaneous analysis by liquid chromatography tandem mass spectrometryJournal of Chromatography B, 2014
- Alkaptonuria is a novel human secondary amyloidogenic diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: Implications in alkaptonuriaJournal of Cellular Physiology, 2012
- The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuriaArthritis & Rheumatism, 2011
- Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigmentRheumatology, 2010
- Crystal structure of human homogentisate dioxygenase.Nature Structural & Molecular Biology, 2000
- The Human Homogentisate 1,2-Dioxygenase (HGO) GeneGenomics, 1997